GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Investments And Advances

Abivax (STU:2X1) Investments And Advances : €0.13 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Abivax Investments And Advances?

Abivax's Investments And Advances for the quarter that ended in Dec. 2024 was €0.13 Mil.

Abivax's quarterly Investments And Advances increased from Jun. 2023 (€0.06 Mil) to Dec. 2023 (€0.12 Mil) and increased from Dec. 2023 (€0.12 Mil) to Dec. 2024 (€0.13 Mil).

Abivax's annual Investments And Advances increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.12 Mil) and increased from Dec. 2023 (€0.12 Mil) to Dec. 2024 (€0.13 Mil).


Abivax Investments And Advances Historical Data

The historical data trend for Abivax's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Investments And Advances Chart

Abivax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 - - 0.12 0.13

Abivax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.82 - 0.06 0.12 0.13

Abivax Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Abivax Business Description

Industry
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines